...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Shareholders

The Eastern share total that Koo posted is the same as what's in the August 2018 press release.  Also, lots of warrants expired unless they were extended.

Share
New Message
Please login to post a reply